Alnylam & Collaborators to Present APOLLO Phase 3 Study Results at 1st European ATTR Amyloidosis Meeting for Patients & Doctors
October 20 2017 - 7:00AM
Business Wire
– Company to Host Conference Call on Thursday,
November 2, 2017, at 12:30 pm ET to Discuss Results –
Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi
therapeutics company, announced today that the results of the
APOLLO Phase 3 study of patisiran in hereditary ATTR (hATTR)
amyloidosis patients with polyneuropathy, as well as additional
posters on patisiran and hATTR amyloidosis, will be presented at
the 1st European ATTR Amyloidosis Meeting for Patients and Doctors
being held November 2-3, 2017 in Paris, France.
Presentations include:
- Patisiran, an investigational RNAi
therapeutic for patients with hereditary transthyretin-mediated
(hATTR) amyloidosis with polyneuropathy: Results from the Phase 3
APOLLO studyAuthors: D Adams, A Gonzalez-Duarte, W O'Riordan,
CC Yang, T Yamashita, A Kristen, I Tournev, H Schmidt, T Coelho, JL
Berk, KP Lin, PJ Dyck, P Gandhi, M Sweetser, J Chen, J Gollob, O
SuhrPresentation type: OralDate/time: November 2, 2017, 3:35 pm
CET
- Long-term, open-label clinical
experience with patisiran, an investigational RNAi therapeutic for
patients with hereditary transthyretin-mediated (hATTR) amyloidosis
with polyneuropathyAuthors: JL Berk, D Adams, O Suhr, I
Conceicao, M Waddington Cruz, H Schmidt, J Buades, J Campistol, J
Pouget, M Polydefkis, AM Partisano, M Sweetser, J Chen, J Gollob, T
CoelhoPresentation type: PosterDate: November 2-3, 2017
- Reasons for Discontinuation of TTR
Stabilizers and/or TTR Fibril Disrupter: An Analysis of Baseline
Demographics of Patients with hATTR Amyloidosis in the Phase 3
APOLLO StudyAuthors: H Schmidt, W O’Riordan, T Yamashita, JL
Berk, I Tournev, M Mezei, V Plante-Bordeneuve, Y Sekijima, OB Suhr,
G Vita, AM Partisano, J Gollob, D AdamsPresentation type:
PosterDate: November 2-3, 2017
- Characteristics of patients with
hereditary transthyretin-mediated amyloidosis on the US liver
transplant waiting listAuthors: D Brandman, SA Živković, W
Irish, LM Gache, A McManus, J Gollob, AM Partisano, S
AgarwalPresentation type: PosterDate: November 2-3, 2017
Alnylam management will discuss these results via conference
call on Thursday, November 2, 2017, at 12:30 p.m. ET. A slide
presentation will also be available on the Investors page of the
Company’s website, www.alnylam.com, to accompany the conference
call. To access the call, please dial 877-312-7507 (domestic) or
631-813-4828 (international) five minutes prior to the start time
and refer to conference ID 2354344. A replay of the call will be
available beginning at 3:30 p.m. ET on the day of the call. To
access the replay, please dial (855) 859-2056 (domestic) or (404)
537-3406 (international), and refer to conference ID 2354344.
About Alnylam Pharmaceuticals
Alnylam (Nasdaq: ALNY) is leading the translation of RNA
interference (RNAi) into a whole new class of innovative medicines
with the potential to transform the lives of people afflicted with
rare genetic, cardio-metabolic, and hepatic infectious diseases.
Based on Nobel Prize-winning science, RNAi therapeutics represent a
powerful, clinically validated approach for the treatment of a wide
range of severe and debilitating diseases. Founded in 2002, Alnylam
is delivering on a bold vision to turn scientific possibility into
reality, with a robust discovery platform and deep pipeline of
investigational medicines, including four product candidates that
are in late-stage development. Looking forward, Alnylam will
continue to execute on its "Alnylam 2020" strategy of building a
multi-product, commercial-stage biopharmaceutical company with a
sustainable pipeline of RNAi-based medicines to address the needs
of patients who have limited or inadequate treatment options.
Alnylam employs over 600 people in the U.S. and Europe and is
headquartered in Cambridge, MA. For more information about our
people, science and pipeline, please visit www.alnylam.com and
engage with us on Twitter at @Alnylam or on LinkedIn.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171020005202/en/
Alnylam Pharmaceuticals, Inc.Investors and
Media:Christine Regan Lindenboom, 617-682-4340orInvestors:Josh
Brodsky, 617-551-8276
Alnylam Pharmaceuticals (NASDAQ:ALNY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Alnylam Pharmaceuticals (NASDAQ:ALNY)
Historical Stock Chart
From Apr 2023 to Apr 2024